Italy: market value of biopharmaceuticals 2017, by type

Published by
Juliette Gagliardi,
Dec 19, 2022
This statistic depicts the market value of biopharmaceuticals becoming off-patent between 2017 and 2022 in Italy as of 2017, by type. According to data, Adalimumab and Trastuzumab generated the greatest market values over the year considered, with 270 and 266 million euros, respectively.

Market value of biopharmaceuticals becoming off-patent between 2017 and 2022 in Italy as of 2017, by type (in million euros)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

July 2018

Region

Italy

Survey time period

2017

Supplementary notes

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars in Italy "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars in Italy

Global overview

5

Generic drugs overview

7

Generics' expenditure

5

Generics' consumption

3

Biosimilar drugs

5

Outlook

5

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Biotech drugsGlobal pharmaceutical industryCancer in the U.S.AmgenCoronavirus (COVID-19) vaccines and treatments
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.